Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma

Marc C. Chamberlain; Michael Glantz; Lisa Chalmers; Alixis Van Horn; Andrew E. Sloan

doi:10.1007/s11060-006-9241-y

Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma

Marc C. Chamberlain
, Michael Glantz
, Lisa Chalmers
, Alixis Van Horn
, Andrew E. Sloan

Research output: Contribution to journal › Article › peer-review

329 Scopus citations

Abstract

Concurrent temozolomide (TMZ) and radiotherapy is the new standard of care for patients with newly diagnosed glioblastoma. In 51 consecutive patients treated according to this regimen, 7 patients (14%) manifested surgically confirmed early necrosis without evidence of recurrent tumor. This observation suggests that daily TMZ may represent a potent radiosensitizing regimen.

Original language	English (US)
Pages (from-to)	81-83
Number of pages	3
Journal	Journal of neuro-oncology
Volume	82
Issue number	1
DOIs	https://doi.org/10.1007/s11060-006-9241-y
State	Published - Mar 1 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Oncology
Neurology
Clinical Neurology
Cancer Research

Access to Document

10.1007/s11060-006-9241-y

Cite this

@article{3bf0c2ebda0146379bd3435a84ffce8b,

title = "Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma",

abstract = "Concurrent temozolomide (TMZ) and radiotherapy is the new standard of care for patients with newly diagnosed glioblastoma. In 51 consecutive patients treated according to this regimen, 7 patients (14\%) manifested surgically confirmed early necrosis without evidence of recurrent tumor. This observation suggests that daily TMZ may represent a potent radiosensitizing regimen.",

author = "Chamberlain, \{Marc C.\} and Michael Glantz and Lisa Chalmers and \{Van Horn\}, Alixis and Sloan, \{Andrew E.\}",

year = "2007",

month = mar,

day = "1",

doi = "10.1007/s11060-006-9241-y",

language = "English (US)",

volume = "82",

pages = "81--83",

journal = "Journal of neuro-oncology",

issn = "0167-594X",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma

AU - Chamberlain, Marc C.

AU - Glantz, Michael

AU - Chalmers, Lisa

AU - Van Horn, Alixis

AU - Sloan, Andrew E.

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Concurrent temozolomide (TMZ) and radiotherapy is the new standard of care for patients with newly diagnosed glioblastoma. In 51 consecutive patients treated according to this regimen, 7 patients (14%) manifested surgically confirmed early necrosis without evidence of recurrent tumor. This observation suggests that daily TMZ may represent a potent radiosensitizing regimen.

AB - Concurrent temozolomide (TMZ) and radiotherapy is the new standard of care for patients with newly diagnosed glioblastoma. In 51 consecutive patients treated according to this regimen, 7 patients (14%) manifested surgically confirmed early necrosis without evidence of recurrent tumor. This observation suggests that daily TMZ may represent a potent radiosensitizing regimen.

UR - https://www.scopus.com/pages/publications/33846955124

UR - https://www.scopus.com/pages/publications/33846955124#tab=citedBy

U2 - 10.1007/s11060-006-9241-y

DO - 10.1007/s11060-006-9241-y

M3 - Article

C2 - 16944309

AN - SCOPUS:33846955124

SN - 0167-594X

VL - 82

SP - 81

EP - 83

JO - Journal of neuro-oncology

JF - Journal of neuro-oncology

IS - 1

ER -

Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this